GraniteShares YieldBOOST Biotech ETF(BIOY)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
SELL
SELL for 1 day
PROFIT SINCE LAST BUY
-5.28% ▼
LAST CLOSE
$17.77
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BIOY

11/20/2026: BIOY (1-star) is a SELL. SELL for 1 day. Simulated Profits (-5.28%). Updated daily EoD!

The GraniteShares YieldBOOST Biotech ETF (BIOY) is an actively managed fund designed to generate high weekly income by selling put options on leveraged ETFs tracking the biotech sector. Its main strengths lie in its specialized derivative overlay that captures rich option premiums from a volatile industry. Its primary use case is serving as a high-yield tactical income vehicle for risk-tolerant portfolios. Key risks include severe sector concentration, high volatility, and capped capital appreciation upside during rallies. It suits aggressive income investors who closely monitor market trends and sector momentum.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

ETF holdings, costs, diversification, valuation, risks, and market conditions provide supporting context about the fund.

Investor Fit

Investor styleFitWhy
Growth investorWeak fitThe fund focuses heavily on income generation and options premium capture rather than long-term capital appreciation.
Momentum investorStrong fit while signal remains positiveTactical momentum traders can leverage the fund's sensitivity to high-beta biotech moves when market trends turn positive.
Value investorWeak fitThe fund relies on high-volatility derivative strategies rather than fundamental valuation metrics.
Dividend/Income investorStrong fitBIOY is specifically tailored to generate high, frequent weekly income distributions via options premiums.
Low-risk investorWeak fitThe underlying asset exposure to biotech and leveraged options creates substantial risk and volatility.

Investor Profile

Ideal Investor Profile

Tactical income-seeking investors looking for high-yield weekly payouts who are comfortable with the severe price swings and risks inherent to the biotechnology sector.

Suitability

Best suited for active traders and tactical income seekers rather than buy-and-hold passive index investors.

Risk Profile

Risk factorLevelWhy it matters
VolatilityHighBiotechnology stocks and options overlays experience sharp price swings.
Market riskHighThe fund is vulnerable to broad downturns in the healthcare and biotech sectors.
ConcentrationHighExposure is narrowly concentrated within a single high-beta sector.
Tracking/expenseMediumActive option overlays and management fees impact net tracking efficiency.
LiquidityMedium / highLower AUM can translate into wider spreads during stressed market conditions.
Business/sector qualityMedium / highBiotech firms often depend on binary clinical or regulatory outcomes.

Sector & Industry Intelligence

This fund is not assigned to one sector.

Risk Analysis

Volatility

BIOY exhibits high historical volatility due to its alignment with the volatile biotechnology sector and leveraged options components.

Market Risk

Subject to substantial market risk stemming from adverse regulatory shifts, clinical failures, and overall equity market pullbacks.

What the ETF Owns

Exposure TypeExposureWeight (%)Retail Investor Read
Fixed-income typeShort-term US Treasury Bills / Cash Collateral57Provides safe collateral backing for the fund's active derivatives and options overlay.
DerivativesOptions Clearing Corporation (Put Options / Swaps Overlay)43Facilitates the active option-selling strategy designed to generate high weekly income distributions.

Price Behavior

Steady Uptrend
PRICE PATH

Steady Uptrend

The stock demonstrates consistent and steady upward price momentum.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type ETF
Historic Profit -5.8%
Avg. Invested days 23
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
ETF Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026
Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.